GIMAP8 Inhibitors
Chemical inhibitors of GIMAP8 function by disrupting the signaling pathways that are essential for its activity and stability. Wortmannin and LY294002 are both potent inhibitors of phosphoinositide 3-kinases (PI3K), which play a pivotal role in intracellular signaling. By inhibiting PI3K, these chemicals prevent the phosphorylation and activation of downstream targets involved in cell survival, which is integral to the function of GIMAP8. Similarly, U0126 and PD98059 target MEK1/2 and MEK respectively, which are upstream regulators of the extracellular signal-regulated kinase (ERK) pathway. Inhibition of these kinases results in reduced ERK pathway activity, which can affect the regulation of GIMAP8. Additionally, SB203580 and SP600125 obstruct the MAPK pathway by selectively inhibiting p38 MAPK and c-Jun N-terminal kinase (JNK), respectively. These kinases are involved in cellular responses to stress and cytokines, and their inhibition can change the cellular environment in which GIMAP8 operates.
Continuing with this theme of pathway interference, Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a kinase that is central to cell growth and metabolism signaling. This inhibition can perturb the processes in which GIMAP8 is involved. PP2, on the other hand, inhibits Src family kinases, which are implicated in various signaling pathways, including those that intersect with the regulatory mechanisms of GIMAP8. BAY 11-7082 disrupts the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, which is crucial for cell survival signals that GIMAP8 may rely on. LY3214996 specifically inhibits ERK1/2, thus affecting the MAPK signaling pathway, which is involved in cell proliferation and survival, and consequently the function of GIMAP8. Lastly, PF-562271 and Dasatinib target focal adhesion kinase (FAK) and Src family kinases along with BCR-ABL, respectively. The inhibition of these kinases by PF-562271 can affect cellular adhesion and migration processes, while Dasatinib's broad-spectrum activity can alter multiple signaling pathways, both of which are important for the regulation of GIMAP8's activity within cells.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as a potent inhibitor of PI3K, a kinase involved in signaling pathways that regulate cell survival and apoptosis. By inhibiting PI3K, this compound can reduce the activation of downstream effectors that may be critical for the function and stability of GIMAP8, leading to its functional inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a specific inhibitor of PI3K, LY294002 prevents the activation of the PI3K/AKT pathway. Given the role of this pathway in cell survival, the inhibition of PI3K can disrupt signals that maintain the stability or activity of GIMAP8. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 selectively inhibits MEK1/2, components of the MAPK/ERK pathway. This inhibition can suppress the phosphorylation and activation of downstream kinases which may be necessary for the functional activity of GIMAP8. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. By hindering p38 MAPK, SB203580 may disrupt signaling pathways that could be crucial for the regulation of GIMAP8 activity, resulting in its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which participates in stress-activated protein kinase pathways. Inhibition of JNK can alter transcription factor activities and other downstream processes that may be vital for GIMAP8 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR, a central regulator of cell growth and metabolism. By inhibiting mTOR, Rapamycin can disrupt signaling pathways important for the activity and stability of GIMAP8. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor. Src kinases are involved in various signaling pathways that could intersect with the regulatory mechanisms of GIMAP8, leading to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which prevents the activation of the ERK pathway. The ERK pathway can influence numerous cellular functions, and its inhibition may lead to the suppression of GIMAP8 activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB, a transcription factor that plays a role in immune response and cell survival. By inhibiting NF-κB, this chemical can lead to the functional inhibition of GIMAP8 through the disruption of critical survival signals. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
LY3214996 specifically inhibits ERK1/2, which can affect the MAPK signaling pathway. This pathway is involved in cell proliferation and survival, and its inhibition may impact the function of GIMAP8. | ||||||